Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date

Breast cancer remains the second leading cause of cancer mortality in women. Endocrine therapy is the backbone treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the most common subtype. Although several endocrine therapy agents are...

Descripción completa

Detalles Bibliográficos
Autores principales: Varella, Leticia, Cristofanilli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041978/
https://www.ncbi.nlm.nih.gov/pubmed/36993871
http://dx.doi.org/10.2147/OTT.S400563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041978/
https://www.ncbi.nlm.nih.gov/pubmed/36993871
http://dx.doi.org/10.2147/OTT.S400563

Ejemplares similares